dc.contributor |
Universitat de Vic - Universitat Central de Catalunya. Càtedra de la Sida i Malalties Relacionades |
|
dc.contributor.author |
Santos, José R.
|
|
dc.contributor.author |
Saumoy, M.
|
|
dc.contributor.author |
Curran, Adrian
|
|
dc.contributor.author |
Bravo, Isabel
|
|
dc.contributor.author |
Llibre, Josep M.
|
|
dc.contributor.author |
Navarro, Jordi
|
|
dc.contributor.author |
Estany, Carla
|
|
dc.contributor.author |
Podzamczer Palter, Daniel
|
|
dc.contributor.author |
Ribera, Esteban
|
|
dc.contributor.author |
Negredo, Eugenia
|
|
dc.contributor.author |
Clotet, Bonaventura
|
|
dc.contributor.author |
Paredes, Roger
|
|
dc.date.accessioned |
2015-11-03T08:32:37Z |
|
dc.date.available |
2015-11-03T08:32:37Z |
|
dc.date.created |
2015 |
|
dc.date.issued |
2015 |
|
dc.identifier.citation |
Santos, J. R., Saumoy, M., Curran, A., Bravo, I., Llibre, J. M., Navarro, J., et al. (2015). The lipid-lowering effect of Tenofovir/Emtricitabine: A randomized, crossover, double-blind, placebo-controlled trial. Clinical Infectious Diseases, 61(3), 403-408. |
ca_ES |
dc.identifier.issn |
1537-6591 |
|
dc.identifier.uri |
http://hdl.handle.net/10854/4333 |
|
dc.description.abstract |
Background. It is unknown if tenofovir disoproxil fumarate (TDF), which is often coformulated with the lipidneutral
emtricitabine (FTC), has a lipid-lowering effect.
Methods. We performed a randomized, crossover, double-blind, placebo-controlled clinical trial on human immunodeficiency
virus type 1 (HIV-1)–infected subjects with HIV-1 RNA < 50 copies/mL during ≥6 months on stable
darunavir/ritonavir (800/100 mg once daily) or lopinavir/ritonavir (400/100 mg twice daily) monotherapy,
fasting total cholesterol (TC) ≥200 mg/dL or low-density lipoprotein cholesterol (LDL-c) ≥130 mg/dL, and no
lipid-lowering drugs. In arm 1, TDF/FTC was added for 12 weeks, followed by 12 weeks of placebo (washout)
and 12 additional weeks of placebo ( placebo period). Subjects in arm 2 added placebo for 12 weeks ( placebo period)
followed by TDF/FTC for 12 weeks and placebo for 12 additional weeks (washout). The primary endpoint was change
in median fasting TC levels.
Results. Of 46 subjects enrolled, 56% received darunavir/ritonavir and 44% lopinavir/ritonavir. Exposure to
TDF/FTC reduced TC from 234 to 205 mg/dL (P < .001), LDL-c from 155 to 128 mg/dL (P < .001), and high-density
lipoprotein cholesterol (HDL-c) from 50.3 to 44.5 mg/dL (P < .001). It also decreased the proportion of subjects with
fasting TC ≥200 mg/dL from 86.7% to 56.8% (P = .001), and LDL-c ≥130 mg/dL from 87.8% to 43.9% (P < .001).
After 12 weeks, TDF/FTC exposure was associated with lower TC and LDL-c levels than placebo (P = .001 and
P = .002, respectively). The TC/HDL-c ratio and triglyceride levels did not change with TDF/FTC exposure.
Conclusions. Coformulated TDF/FTC has an intrinsic lipid-lowering effect, likely attributable to TDF. |
ca_ES |
dc.format |
application/pdf |
|
dc.format.extent |
6 p. |
ca_ES |
dc.language.iso |
eng |
ca_ES |
dc.publisher |
Oxford University Press |
ca_ES |
dc.rights |
Tots els drets reservats |
ca_ES |
dc.rights |
(c) OUP |
|
dc.subject.other |
Sida -- Tractament |
ca_ES |
dc.subject.other |
VIH (Virus) |
ca_ES |
dc.title |
The Lipid-Lowering Effect of Tenofovir/ Emtricitabine: A Randomized, Crossover, Double-Blind, Placebo-Controlled Trial |
ca_ES |
dc.type |
info:eu-repo/semantics/article |
ca_ES |
dc.identifier.doi |
https://doi.org/10.1093/cid/civ296 |
|
dc.rights.accessRights |
info:eu-repo/semantics/closedAccess |
ca_ES |
dc.type.version |
info:eu-repo/publishedVersion |
ca_ES |
dc.indexacio |
Indexat a WOS/JCR |
ca_ES |
dc.indexacio |
Indexat a SCOPUS |
ca_ES |